Skip Navigation

News & Resources


Subscribe to NHLBI Press Releases
Subscribe to NHLBI In The News
June 14, 2016 : JAMA

A study has shown that long-acting opioids — such as sustained-release morphine and controlled-release oxycodone — for chronic pain relief increase the risk of death from cardiovascular and other causes. In the study, funded by the National Heart, Lung, and Blood Institute, the researchers compared long-acting opioid use to the use of anticonvulsants or antidepressants for chronic pain unrelated to cancer. They found that prescription opioid use was associated with more deaths. The deaths were mostly for reasons other than an unintentional overdose, and more than half of these were cardiovascular related. The researchers recommend that their findings be considered when evaluating the harms and benefits of pain treatment.

May 30, 2016 : Nature Materials

Through a study funded in part by the National Heart, Lung, and Blood Institute, researchers gained new insights into the biological basis of single-cell mechanical homeostasis — the process by which a cell strives to maintain stability despite physical stressors on its surface. They found that on a single-cell level, mechanical homeostasis is driven by distinct regulation of activities involving the cytoskeleton, which gives shape and structure to cells. Also important was the regulation of structures called focal adhesions, which control the transmission of mechanical forces to the cells. The authors note that understanding single-cell mechanical homeostasis can provide critical insights into how cellular dysregulation can develop and lead to cardiovascular disease and other disorders.

June 29, 2016
This Webinar will present NHLBI’s efforts to optimize its clinical trials enterprise by working with its investigator community to foster trial success and maximize the benefits of this research to society and public health. The Webinar will highlight a new initiative to facilitate the conduct and management of clinical trials by establishing early on clear milestones and metrics of progress through the Institute’s Funding Opportunity Announcements (FOAs) – the notices by which NHLBI solicits applications for research from its investigator community. Specifically, presenters in this webinar will describe the specific performance milestones and metrics to be included in applications for multi-site clinical trials (Phase II and above), and will answer investigator questions about NHLBI’s new approach, with an eye toward helping them prepare the best applications possible.
July 6, 2016 to July 7, 2016
National Institutes of Health Building 31, Wing C, Conference Room 10 Bethesda, MD 20892
The proposed workshop will foster the discussion of: The goal of this workshop is to bring together experts to discuss the needed evidence on efficacy, effectiveness and patient safety of pharmacological and non-pharmacological therapies for heart, lung, and blood disorders and their risk factors among Hispanics/Latinos, accounting for their racial/ethnic, genetic, socioeconomic and cultural diversity.